Recurrent Ovarian Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01116648Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerTreatment
NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianTreatment